7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …

Purpose This phase II study evaluated efficacy of single-agent erlotinib for chemotherapy-
naïve patients with advanced/metastatic NSCLC who were ineligible for platinum doublets …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …

Purpose Erlotinib prolongs survival in patients with advanced non–small-cell lung cancer
(NSCLC). We report the results of a randomized, phase II study of erlotinib alone or …

Methods Previously treated patients with EGFR TKI–naive advanced NSCLC were randomly
assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or …

Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …